China, Brazil Should Not Be In AIDS Drug Patent Pool, Gilead Says
This article was originally published in PharmAsia News
Executive SummaryHONG KONG - The number of partnerships among multinational pharmaceutical companies for HIV/AIDS drugs is on the rise, driven in part by the growing need for combination products to which no single company owns all the patents
You may also be interested in...
Gilead may face unexpected speed bumps related to Sovaldi patents in India as it tries to extend the reach of its breakthrough HCV treatment via a combination of strategies, including voluntary licenses with Indian generics firms.
Gilead’s decision to donate Viread to Chinese HIV patients came at a time when China was updating its compulsory license rules. The U.S. company may have also been thinking about the potential ramifications for hepatitis B, a much larger market in China.